Galderma, the emerging pure-play dermatology category leader, will be showcasing its innovative, science-based portfolio that spans the full spectrum of the fast-growing dermatology market at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting.
Details on scientific presentations supported by Galderma at AAD 2024 can be found below.
|
First author |
Abstract title and number |
Presentation time and location |
|
Late-breaking presentations |
||
|
J. Silverberg
|
Abstract #56887 Maintenance of efficacy and safety with nemolizumab* at Week 48: results from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in patients with moderate-to-severe atopic dermatitis
|
Sunday, March 10, 2024, 2:50 PM PST
Upper Level, Room 20BCD |
|
S. Kwatra
|
Abstract #56884 Nemolizumab* long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: an interim analysis
|
Sunday, March 10, 2024, 3:20 PM PST
Upper Level, Room 20BCD |
|
Oral posters |
||
|
A. Alexis
|
Abstract #53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types
|
Friday, March 8, 2024, 8:35 to 8:40 AM PST
Upper Level, Sails Pavilion, Poster Center 1
|
|
A. Alexis
|
Abstract #53113 Trifarotene shown to improve acne and related sequelae
|
Friday, March 8, 2024, 9:05 to 9:10 AM PST
Upper Level, Sails Pavilion, Poster Center 1
|
|
S. Schlessinger
|
Abstract #53083 Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA**, when used for combination treatment of glabellar and lateral canthal lines
|
Friday, March 8, 2024, 9:50 to 9:55 AM PST
Upper Level, Sails Pavilion, Poster Center 1
|
|
C. Whiting
|
Abstract #52929 Primary hyperhidrosis and sensitive skin syndrome: a national pilot survey†
|
Friday, March 8, 2024, 10:10 to 10:15 AM PST
Upper Level, Sails Pavilion, Poster Center 1 |
|
S.A. Azim
|
Abstract #54376 Sensitive skin: a survey of dermatology resident physicians’ perspectives and educational exposures†
|
Friday, March 8, 2024, 3:50 to 3:55 PM PST
Upper Level, Sails Pavilion, Poster Center 1
|
|
E-posters |
||
|
J. Manjunath
|
Abstract #52517 Association between prurigo nodularis and cognitive impairment: A retrospective matched cohort study
|
E-posters are accessible online starting Friday, March 8. Meeting attendees may also visit the e-poster viewing stations, located at the Sail Pavilion on the second floor in the San Diego Convention Center
|
|
J. Cohen
|
Abstract #54283 Upward brow position change after treatment with abobotulinumtoxinA in the glabellar lines
|
|
|
R. Siperstein
|
Abstract #49785 Long-term 23-year global post-marketing safety surveillance review of delayed complications with a supportive filler for infraorbital hollow rejuvenation
|
|
|
J. Waibel
|
Abstract #52823 A randomized, comparative study describing the gene signatures of poly-L-Lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds
|
|
|
K.K. Durairaj
|
Abstract #52490 A multi-center, retrospective, chart review to evaluate the safety of poly-L-lactic acid injectable implant when used in non-facial areas
|
|
|
Y. Nong
|
Abstract #48854 Treatment with encapsulated benzoyl peroxide leads to a durable shift in the microbiome in rosacea
|
|
|
A. Alexis
|
Abstract #51125 Patient exit interviews illustrate benefit of trifarotene on acne-induced pigmentary problems
|
|
|
M. Grivet-Seyve
|
Abstract #53537 Sensitive skin syndrome: a meta-analysis of clinical trials evaluating the benefits of dermocosmetics on itch in sensitive skin subjects
|
|
|
I. Berlin
|
Abstract #53851 Diverse & inclusive understanding of sensitive skin: A worldwide profiling
|
|
|
G. Pellacani
|
Abstract #53019 Efficacy and tolerability of a face serum targeting healthy aging in subjects with sensitive skin
|
|
|
N. Joly-Tonetti
|
Abstract #53136 In vitro and in vivo evaluation of a new healthy aging skin care strategy for sensitive skin
|
|
|
M. Grivet-Seyve
|
Abstract #54331 Sensitive skin syndrome: a meta-analysis of clinical trials evaluating the impact of dermocosmetics on itch
|
|
|
N. Piccardi
|
Abstract #51725 Importance of a tailored skin care routine for patients with moderate acne vulgaris and post-inflammatory hyperpigmentation treated with topical trifarotene
|
|
|
T. Nguyen
|
Abstract #53990 Heatmap evaluation of body hydration
|
|
|
A. Farberg
|
Abstract #54048 Safety and efficacy of a healing ointment post-surgical wound care
|
|
|
T. Nguyen
|
Abstract #54134 A novel 3-step OTC eczema regimen improves eczema severity, itch, and life quality: randomized study
|
All authors are paid consultants or employees of Galderma.
* Nemolizumab is an investigational drug and Galderma has not received approval for any indication in any country.
** RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country.
†Posters were developed as part of a Galderma Global Sensitive Skincare Faculty and George Washington University collaboration.